Ignite Creation Date:
2024-10-26 @ 3:40 PM
Last Modification Date:
2024-10-26 @ 3:40 PM
Study NCT ID:
NCT06605690
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-09-18
Brief Title:
An Exploratory Clinical Study of Dalpiciclib anAmp39d Letrozole Combined With Anlotinib Neoadjuvant Therapy in Stage II-III Postmenopausal HRHER2- Early Breast Cancer
Sponsor:
None
Organization:
None
Study Overview
Official Title:
An Exploratory Clinical Study of Dalpiciclib anAmp39d Letrozole Combined With Anlotinib Neoadjuvant Therapy in Stage II-III Postmenopausal HRHER2- Early Breast Cancer
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a single-arm open-label exploratory clinical study
Detailed Description:
This is a single-arm open-label exploratory clinical study initiated by the investigator to evaluate the objective response rate ORR efficacy and safety of Dalpiciclib and letrozole combined with Anlotinib in the neoadjuvant treatment of stage Ⅱ-Ⅲ Postmenopausal HRHER2- breast cancer
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None